Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00583128 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

A Phase 2 study, sponsored by Ocera Therapeutics.

Completed
Registry status
Phase 2
Development phase
117
Enrollment target

NCT00583128: Completed Phase 2 study, sponsored by Ocera Therapeutics.

NCT00583128 is a Phase 2 study that has completed, run by Ocera Therapeutics. The registered enrollment target is 117 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (12% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00583128, a Phase 2 study, has completed, sponsored by Ocera Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
117 participants
Enrollment target

Study Summary

The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with non-constipating IBS. The study will test whether or not patients receiving AST-120 experience at least a 50% reduction in the number of days with abdominal pain compared to placebo.

Interventions

  • DRUG AST-120
  • DRUG Celphere® CP-305

Trial Details

FieldValue
Enrollment Target 117 participants
Start Date 2007-08
Est. Completion 2010-06
Phase Phase 2
Ocera Therapeutics

9 total trials

What the finished NCT00583128 record still lists

NCT00583128 is an interventional study that assigns participants to a tested intervention. The registered 117 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (12% lower).

The record links to 0 conditions, and to 2 interventions - of which AST-120 is the first listed.

NCT00583128 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00583128 about?

NCT00583128 is a clinical study titled "Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome". The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with non-constipating IBS. The study will test whether or not patients receiving AST-120 experience at least a 50% reduction in the number of days with abdominal pain compare...

What is the current status of trial NCT00583128?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 117 participants. The study started on 2007-08. Estimated completion is 2010-06.

What interventions are being tested in trial NCT00583128?

The interventions under investigation include: AST-120 (DRUG), Celphere® CP-305 (DRUG).

Who is sponsoring clinical trial NCT00583128?

This trial is sponsored by Ocera Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00583128's enrollment target sits among peer trials

117 623rd of 2000 higher than 1,378 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03539822 · 117 participants · Phase 1

    Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

  • NCT03786692 · 117 participants · Phase 2

    Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC

  • NCT04479696 · 117 participants · NA

    Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors

  • NCT04940585 · 117 participants · NA

    ROSE in Sunset Park

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00583128, the US trial registry maintained by the National Library of Medicine. NCT00583128 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.